TAP Biosystems, a leading supplier of innovative cell culture and fermentation systems for life science applications, today announced that it will be co-presenting a new 3D cell culture webinar with BioTek Instruments on Thursday, Feb 27, 2014 at 12:00 PM EST. The live event will offer free access to new scientific presentations demonstrating the benefits of using 3D cell culture including RAFT™ 3D collagen-based technology in oncology research and toxicology screening.

Two 3D cell culture experts, Brad Larson, Principal Scientist at BioTek Instruments, and Dr Grant Cameron, TAP Biosystems’ RAFT Development Director will be presenting data derived from oncology and toxicology studies. They will discuss the capability of two types of 3D cell culture methods, incorporating either collagen hydrogels with RAFT 3D cell culture technology or a spheroid method of 3D cell culture. Both specialists will provide data generated using microplate-based assays and fluorescence imaging to show that cells cultured in 3D maintain greater viability and function over extended time periods compared to 2D cell culture, and will explain how using 3D cell culture may provide better correlation to clinical testing in oncology and long-term cytotoxicity studies.

To join the webinar, scientists simply need to register at: http://www.tapbiosystems.com/RAFT_webinar/RAFToncwebinar_BioTekPR.htm

Dr Grant Cameron, TAP Biosystems’ RAFT Development Director stated: “Improving drug efficacy and eliminating unexpected cytotoxicity issues prior to clinical trials by making the assays in early drug discovery more biological relevant has been a challenge in the biopharm industry for the past decade. 3D cell culture offers a solution to this issue.”

Cameron continued: “I am therefore delighted to be hosting a webinar alongside Brad Larson in which we’ll demonstrate that cells cultured in 3D provide better mimics of cellular function within living tissue and I look forward to discussing how incorporating 3D cell culture processes into oncology and toxicology screening programmes can contribute to providing more accurate and clinically relevant data.”